Here we show that survival benefit is predicted by high B cell tumor infiltrate together with high TERT expression, but not tumor mutational burden or neaoantigen burden, placing TERT as a key antigen in mediating local antitumor immunity and favorable clinical outcome in HNSCC. This evidence concerns the gene TERT and neoplasm.